Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease

Br J Haematol. 2022 Oct;199(1):40-44. doi: 10.1111/bjh.18378. Epub 2022 Jul 27.

¹ Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
² Department of Haematology, Kings college Hospital, London, UK.
³ UCL Cancer Trials Centre, University College London, London, UK.
⁴ Department of Haematology, Royal Marsden Hospital, London, UK.
⁵ Department of Haematology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.
⁶ Department of Haematology, Oxford University NHS Trust, Oxford, UK.

No abstract available

Keywords: BTKi failure; CAR T-cell therapy; Tecartus; cellular therapy in mantle cell lymphoma; mantle cell lymphoma.

MeSH terms